Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy

Clin Obstet Gynecol. 2016 Dec;59(4):756-771. doi: 10.1097/GRF.0000000000000237.

Abstract

Breast cancer is a heterogenous disease, comprised of at least 3 major subtypes: hormone receptor-positive/HER2-(HR+), HER2+, and HR-/HER2-(triple negative) breast cancers. The medical management of each subype is distinct. In this article, we review contemporary data supporting the use of chemotherapy, endocrine therapy and biologic therapies, especially HER2-directed agents, in the adjuvant and neoadjuvant setting in patients with newly diagnosed nonmetastatic (stage I-III) breast cancer.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Biological Therapy / methods
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Chemotherapy, Adjuvant / methods*
  • Female
  • Genes, BRCA1
  • Genes, BRCA2
  • Genes, erbB-2
  • Humans
  • Neoadjuvant Therapy / methods*
  • Randomized Controlled Trials as Topic
  • Receptors, Estrogen / therapeutic use*
  • Receptors, Progesterone / therapeutic use*

Substances

  • Antineoplastic Agents
  • Receptors, Estrogen
  • Receptors, Progesterone